Answers are grounded in this paper and cite their sources.
Background Preferential phosphodiesterase 4B (PDE4B) inhibition with nerandomilast has demonstrated attenuation of forced vital capacity decline in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Because PDE4 enzymes regulate cAMP-dependent inflammatory and endothelial signalling, class-level PDE4 inhibition has been consistently linked to vascular–immune pathways. Whether preferential PDE4B inhibition reproduces these effects remains uncertain. Objectives To map the available mechanistic and translational literature on extrapulmonary or systemic biological effects of PDE4/PDE4B inhibition and to place nerandomilast trial findings within that framework without inferring clinical efficacy outside pre-specified trial outcomes. Methods We performed a the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews informed scoping review of PubMed/MEDLINE from database inception to 1 March 2026. Eligible studies included pre-clinical, translational and clinical reports addressing endothelial, immune, microvascular or organ-level effects of PDE4/PDE4B modulation. Evidence was charted and narratively synthesised rather than quantitatively pooled. Results 71 studies were included. Experimental data (primarily derived from class-level PDE4 inhibition) consistently link these pathways to modulation of endothelial permeability, leukocyte–endothelial adhesion, thromboinflammatory signalling, and macrophage resolution programmes across pulmonary and extrapulmonary models. However, most extrapulmonary evidence derives from class-level PDE4 biology rather than nerandomilast-specific investigations, and clinical evidence for extrapulmonary benefit in fibrotic lung disease remains indirect. Conclusions Because PDE4 enzymes regulate cAMP-dependent inflammatory and endothelial signalling, class-level PDE4 inhibition has been consistently linked to modulation of vascular–immune pathways. Whether preferential PDE4B inhibition reproduces these effects in humans remains to be established. While at present, extrapulmonary clinical benefit in fibrotic lung disease remains unproven, future studies should prospectively evaluate systemic biomarkers and organ-level outcomes rather than relying on post hoc interpretation of numerical signals.
No takes yet. Share an insight, caveat, or question.
Perrotta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: